Literature DB >> 12439156

Laryngopharyngeal reflux and laryngeal web formation in patients with pediatric recurrent respiratory papillomas.

Bradford W Holland1, James A Koufman, Gregory N Postma, William F McGuirt.   

Abstract

OBJECTIVE: To determine whether treatment of laryngopharyngeal reflux reduces the laryngeal soft tissue complications encountered in surgery for recurrent respiratory papillomas. STUDY
DESIGN: Retrospective chart review.
METHODS: Retrospective chart review of all pediatric patients treated for laryngeal recurrent respiratory papillomas between 1984 and 1999 was performed. Thirty-one such patients were identified. Twenty-four were at "high risk" for developing complications based on the number of operating suite visits and the presence of disease at the anterior commissure. Twelve patients underwent 24-hour double pH probe testing.
RESULTS: Overall, 13 of 31 patients (42%) developed laryngeal webs. No other soft tissue complications were encountered. Of the patients who had pH probe testing, 12 of 12 (100%) had at least one pharyngeal episode of acid exposure. Of the "high-risk" patients, 10 were treated for reflux and only 2 of 10 (20%) developed webs. Eleven of 14 (79%) of the "high-risk" patients who were not treated for reflux developed webs. The difference in rate of web formation between patients treated for reflux and those not treated for reflux was statistically significant (P =.011).
CONCLUSIONS: Antireflux treatments for patients undergoing surgery for laryngeal recurrent respiratory papillomas may reduce the soft tissue complications, especially scarring and web formation. Prophylactic antireflux therapy may be warranted in any patient undergoing surgery during which laryngeal mucosal disruption is anticipated.

Entities:  

Mesh:

Year:  2002        PMID: 12439156     DOI: 10.1097/00005537-200211000-00003

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  12 in total

1.  A Misdiagnosed Laryngeal Web: Treated with an Innovative Self-Made Keel.

Authors:  Kartik Anil Parelkar; Vandana P Thorawade; Keya A Shah; Ankur K Walli; Ankur H Pareek
Journal:  J Clin Diagn Res       Date:  2017-05-01

2.  Prevention of laryngeal webs through endoscopic keel placement for bilateral vocal cord lesions.

Authors:  Jian Chen; Yilai Shu; Matthew R Naunheim; Min Chen; Lei Cheng; Haitao Wu
Journal:  Front Med       Date:  2017-09-26       Impact factor: 4.592

Review 3.  New trends in rehabilitation of children with ENT disorders.

Authors:  R Bovo; P Trevisi; E Zanoletti; D Cazzador; T Volo; E Emanuelli; A Martini
Journal:  Acta Otorhinolaryngol Ital       Date:  2017-10       Impact factor: 2.124

Review 4.  [Current therapeutic options for recurrent respiratory papillomatosis].

Authors:  K Huber; H Sadick; K Götte
Journal:  HNO       Date:  2005-11       Impact factor: 1.284

Review 5.  Laryngopharyngeal reflux disease in children.

Authors:  Naren N Venkatesan; Harold S Pine; Michael Underbrink
Journal:  Pediatr Clin North Am       Date:  2013-08       Impact factor: 3.278

6.  Acquired Glottic Web Formation in a 3-Year-Old Girl: Case Report and Literature Review.

Authors:  Susan D Emmett; Lee M Akst; Margaret L Skinner
Journal:  Int J Pediatr Otorhinolaryngol Extra       Date:  2014-07-10

Review 7.  [Laryngeal papillomatosis: etiology, diagnostics and therapy].

Authors:  M Andratschke; C Betz; A Leunig
Journal:  HNO       Date:  2008-12       Impact factor: 1.284

Review 8.  Recurrent respiratory papillomatosis.

Authors:  Naren N Venkatesan; Harold S Pine; Michael P Underbrink
Journal:  Otolaryngol Clin North Am       Date:  2012-06       Impact factor: 3.346

Review 9.  Immunological tolerance of low-risk HPV in recurrent respiratory papillomatosis.

Authors:  R Ivancic; H Iqbal; B deSilva; Q Pan; L Matrka
Journal:  Clin Exp Immunol       Date:  2019-10-31       Impact factor: 4.330

Review 10.  Recurrent respiratory papillomatosis: current and future perspectives.

Authors:  Marco Carifi; Domenico Napolitano; Morando Morandi; Danilo Dall'Olio
Journal:  Ther Clin Risk Manag       Date:  2015-05-05       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.